A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

BI 1015550 · Фаза 2

ID реестра
NCT06241560
Фаза
Фаза 2
Статус
Завершено
Препарат / вмешательство
BI 1015550
Спонсор
Boehringer Ingelheim
Начало
2026-03-05
Набор участников
20
Центры
3

Об исследовании

This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are 40 years and older. The purpose of this study is to find out whether a medicine called pirfenidone changes the amount of a medicine called BI 1015550 in the blood. Some people may take more than one medicine at a time. Therefore, it is important to understand how different medicines influence one another. Participants take one dose of BI 1015550 as a tablet. Participants then take one tablet of pirfenidone 3 times a day for one week. The dose is then increased to 2 tablets 3 times a day for the second week. In the third week the dose is increased further to 3 tablets 3 times a day. Participants then take another dose of BI 1015550 as a tablet. Participants are in the study for a little over 1 month. During this

Открыть NCT06241560 на ClinicalTrials.gov →

Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT06241560 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.